{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:52:09Z","timestamp":1794009129693,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PreGoBio program of the Experimental and Clinical Research Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin and Max-Delbr\u00fcck-Center for Molecular Medicine"},{"DOI":"10.13039\/501100012353","name":"German Cancer Consortium","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012353","name":"German Cancer Consortium","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4197-9","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T14:17:52Z","timestamp":1521123472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0964-4174","authenticated-orcid":false,"given":"Susen","family":"Burock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Daum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"4197_CR1","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374\u2013403.","journal-title":"Eur J Cancer"},{"key":"4197_CR2","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/annonc\/mds236","volume":"23","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, Van CE, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479\u2013516.","journal-title":"Ann Oncol"},{"key":"4197_CR3","first-page":"283","volume":"4","author":"GP Kanas","year":"2012","unstructured":"Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283\u2013301.","journal-title":"Clin Epidemiol"},{"key":"4197_CR4","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(94)92529-1","volume":"343","author":"R Stangl","year":"1994","unstructured":"Stangl R, Altendorf-Hofmann A, Charnley RM, et al. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405\u201310.","journal-title":"Lancet"},{"issue":"Suppl 3","key":"4197_CR5","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","volume":"25","author":"CE Van","year":"2014","unstructured":"Van CE, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii1\u20139.","journal-title":"Ann Oncol"},{"key":"4197_CR6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","volume":"352","author":"P Rougier","year":"1998","unstructured":"Rougier P, Van CE, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407\u201312.","journal-title":"Lancet"},{"key":"4197_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","volume":"370","author":"MT Seymour","year":"2007","unstructured":"Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370:143\u201352.","journal-title":"Lancet"},{"key":"4197_CR8","first-page":"1","volume":"1653","author":"RH Giles","year":"2003","unstructured":"Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003;1653:1\u201324.","journal-title":"Biochim Biophys Acta"},{"key":"4197_CR9","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1053\/j.gastro.2006.08.041","volume":"131","author":"U Stein","year":"2006","unstructured":"Stein U, Arlt F, Walther W, et al. The metastasis-associated gene S100A4 is a novel target of beta-catenin\/T-cell factor signaling in colon cancer. Gastroenterology. 2006;131:1486\u2013500.","journal-title":"Gastroenterology"},{"key":"4197_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1593\/neo.101172","volume":"13","author":"U Stein","year":"2011","unstructured":"Stein U, Arlt F, Smith J, et al. Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia. 2011;13:131\u201344.","journal-title":"Neoplasia"},{"key":"4197_CR11","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.18632\/oncotarget.1908","volume":"5","author":"M Dahlmann","year":"2014","unstructured":"Dahlmann M, Okhrimenko A, Marcinkowski P, et al. RAGE mediates S100A4-induced cell motility via MAPK\/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis. Oncotarget. 2014;5:3220\u201333.","journal-title":"Oncotarget"},{"key":"4197_CR12","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1091\/mbc.E10-09-0739","volume":"22","author":"U Sack","year":"2011","unstructured":"Sack U, Walther W, Scudiero D, et al. S100A4-induced cell motility and metastasis is restricted by the Wnt\/beta-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell. 2011;22:3344\u201354.","journal-title":"Mol Biol Cell"},{"key":"4197_CR13","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/jnci\/djr190","volume":"103","author":"U Sack","year":"2011","unstructured":"Sack U, Walther W, Scudiero D, et al. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst. 2011;103:1018\u201336.","journal-title":"J Natl Cancer Inst"},{"key":"4197_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00109-007-0301-3","volume":"86","author":"M Schneider","year":"2008","unstructured":"Schneider M, Hansen JL, Sheikh SP. S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med (Berl). 2008;86:507\u201322.","journal-title":"J Mol Med (Berl)"},{"key":"4197_CR15","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1038\/sj.bjc.6602613","volume":"92","author":"DM Helfman","year":"2005","unstructured":"Helfman DM, Kim EJ, Lukanidin E, et al. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer. 2005;92:1955\u20138.","journal-title":"Br J Cancer"},{"key":"4197_CR16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/bjc.2012.293","volume":"107","author":"K Boye","year":"2012","unstructured":"Boye K, Nesland JM, Sandstad B, et al. EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer. Br J Cancer. 2012;107:667\u201374.","journal-title":"Br J Cancer"},{"key":"4197_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/1471-2407-12-333","volume":"12","author":"AK Rud","year":"2012","unstructured":"Rud AK, Lund-Iversen M, Berge G, et al. Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer. BMC Cancer. 2012;12:333.","journal-title":"BMC Cancer"},{"key":"4197_CR18","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1016\/j.ejca.2010.07.013","volume":"46","author":"K Boye","year":"2010","unstructured":"Boye K, Nesland JM, Sandstad B, et al. Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer. 2010;46:2919\u201325.","journal-title":"Eur J Cancer"},{"key":"4197_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.2353\/ajpath.2010.090526","volume":"176","author":"K Boye","year":"2010","unstructured":"Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles. Am J Pathol. 2010;176:528\u201335.","journal-title":"Am J Pathol"},{"key":"4197_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1590\/1678-775720140133","volume":"22","author":"J Natarajan","year":"2014","unstructured":"Natarajan J, Hunter K, Mutalik VS, et al. Overexpression of S100A4 as a biomarker of metastasis and recurrence in oral squamous cell carcinoma. J Appl Oral Sci. 2014;22:426\u201333.","journal-title":"J Appl Oral Sci"},{"key":"4197_CR21","first-page":"2828","volume":"18","author":"H Huang","year":"2014","unstructured":"Huang H, Zheng HY, Liu ZL, et al. Prognostic significance of relaxin-2 and S100A4 expression in osteosarcoma. Eur Rev Med Pharmacol Sci. 2014;18:2828\u201334.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4197_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jmoldx.2010.10.002","volume":"13","author":"U Stein","year":"2011","unstructured":"Stein U, Burock S, Herrmann P, et al. Diagnostic and prognostic value of metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients. J Mol Diagn. 2011;13:189\u201398.","journal-title":"J Mol Diagn"},{"key":"4197_CR23","first-page":"1621","volume":"13","author":"NS Ambartsumian","year":"1996","unstructured":"Ambartsumian NS, Grigorian MS, Larsen IF, et al. Metastasis of mammary carcinomas in GRS\/A hybrid mice transgenic for the mts1 gene. Oncogene. 1996;13:1621\u201330.","journal-title":"Oncogene"},{"key":"4197_CR24","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/2211016a0","volume":"221","author":"EC Weinbach","year":"1969","unstructured":"Weinbach EC, Garbus J. Mechanism of action of reagents that uncouple oxidative phosphorylation. Nature. 1969;221:1016\u20138.","journal-title":"Nature"},{"key":"4197_CR25","doi-asserted-by":"publisher","first-page":"10267","DOI":"10.1021\/bi9009677","volume":"48","author":"M Chen","year":"2009","unstructured":"Chen M, Wang J, Lu J, et al. The anti-helminthic niclosamide inhibits Wnt\/Frizzled1 signaling. Biochemistry. 2009;48:10267\u201374.","journal-title":"Biochemistry"},{"key":"4197_CR26","doi-asserted-by":"publisher","first-page":"G293","DOI":"10.1152\/ajpgi.00005.2010","volume":"299","author":"W Chen","year":"2010","unstructured":"Chen W, Chen M, Barak LS. Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach. Am J Physiol Gastrointest Liver Physiol. 2010;299:G293\u2013300.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"4197_CR27","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1158\/0008-5472.CAN-10-3978","volume":"71","author":"T Osada","year":"2011","unstructured":"Osada T, Chen M, Yang XY, et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res. 2011;71:4172\u201382.","journal-title":"Cancer Res"},{"key":"4197_CR28","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2147\/OTT.S50065","volume":"6","author":"M Tomizawa","year":"2013","unstructured":"Tomizawa M, Shinozaki F, Motoyoshi Y, et al. Niclosamide suppresses hepatoma cell proliferation via the Wnt pathway. Onco Targets Ther. 2013;6:1685\u201393.","journal-title":"Onco Targets Ther"},{"key":"4197_CR29","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.fertnstert.2014.01.017","volume":"101","author":"M Ono","year":"2014","unstructured":"Ono M, Yin P, Navarro A, et al. Inhibition of canonical WNT signaling attenuates human leiomyoma cell growth. Fertil Steril. 2014;101:1441\u20139.","journal-title":"Fertil Steril"},{"key":"4197_CR30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1158\/1535-7163.MCT-13-0555","volume":"13","author":"AI Londono-Joshi","year":"2014","unstructured":"Londono-Joshi AI, Arend RC, Aristizabal L, et al. Effect of niclosamide on basal-like breast cancers. Mol Cancer Ther. 2014;13:800\u201311.","journal-title":"Mol Cancer Ther"},{"key":"4197_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ygyno.2014.04.005","volume":"134","author":"RC Arend","year":"2014","unstructured":"Arend RC, Londono-Joshi AI, Samant RS, et al. Inhibition of Wnt\/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecol Oncol. 2014;134:112\u201320.","journal-title":"Gynecol Oncol"},{"key":"4197_CR32","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1038\/onc.2014.277","volume":"34","author":"ML King","year":"2015","unstructured":"King ML, Lindberg ME, Stodden GR, et al. WNT7A\/beta-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 2015;34:3452\u201362.","journal-title":"Oncogene"},{"key":"4197_CR33","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1158\/1078-0432.CCR-15-2256","volume":"22","author":"K Satoh","year":"2016","unstructured":"Satoh K, Zhang L, Zhang Y, et al. Identification of niclosamide as a novel anticancer agent for adrenocortical carcinoma. Clin Cancer Res. 2016;22:3458\u201366.","journal-title":"Clin Cancer Res"},{"key":"4197_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2014.04.003","volume":"349","author":"Y Li","year":"2014","unstructured":"Li Y, Li PK, Roberts MJ, et al. Multi-targeted therapy of cancer by niclosamide: a new application for an old drug. Cancer Lett. 2014;349:8\u201314.","journal-title":"Cancer Lett"},{"key":"4197_CR35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.5732\/cjc.011.10290","volume":"31","author":"JX Pan","year":"2012","unstructured":"Pan JX, Ding K, Wang CY. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer. 2012;31:178\u201384.","journal-title":"Chin J Cancer"},{"key":"4197_CR36","doi-asserted-by":"publisher","first-page":"35769","DOI":"10.1074\/jbc.M113.511212","volume":"288","author":"M Li","year":"2013","unstructured":"Li M, Khambu B, Zhang H, et al. Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity. J Biol Chem. 2013;288:35769\u201380.","journal-title":"J Biol Chem"},{"key":"4197_CR37","doi-asserted-by":"publisher","first-page":"e7124","DOI":"10.1371\/journal.pone.0007124","volume":"4","author":"AD Balgi","year":"2009","unstructured":"Balgi AD, Fonseca BD, Donohue E, et al. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One. 2009;4:e7124.","journal-title":"PLoS One"},{"key":"4197_CR38","doi-asserted-by":"publisher","first-page":"17530","DOI":"10.1074\/jbc.M112.359638","volume":"287","author":"BD Fonseca","year":"2012","unstructured":"Fonseca BD, Diering GH, Bidinosti MA, et al. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem. 2012;287:17530\u201345.","journal-title":"J Biol Chem"},{"key":"4197_CR39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1021\/ml100146z","volume":"1","author":"X Ren","year":"2010","unstructured":"Ren X, Duan L, He Q, et al. Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med Chem Lett. 2010;1:454\u20139.","journal-title":"ACS Med Chem Lett"},{"key":"4197_CR40","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/1078-0432.CCR-12-2895","volume":"19","author":"A Wieland","year":"2013","unstructured":"Wieland A, Trageser D, Gogolok S, et al. Anticancer effects of niclosamide in human glioblastoma. Clin Cancer Res. 2013;19:4124\u201336.","journal-title":"Clin Cancer Res"},{"key":"4197_CR41","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/0008-5472.CAN-09-3950","volume":"70","author":"Y Jin","year":"2010","unstructured":"Jin Y, Lu Z, Ding K, et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res. 2010;70:2516\u201327.","journal-title":"Cancer Res"},{"key":"4197_CR42","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2174\/1568009615666150629132157","volume":"15","author":"Z Liao","year":"2015","unstructured":"Liao Z, Nan G, Yan Z, et al. The anthelmintic drug niclosamide inhibits the proliferative activity of human osteosarcoma cells by targeting multiple signal pathways. Curr Cancer Drug Targets. 2015;15:726\u201338.","journal-title":"Curr Cancer Drug Targets"},{"key":"4197_CR43","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1158\/1535-7163.MCT-12-0002","volume":"11","author":"YT Yo","year":"2012","unstructured":"Yo YT, Lin YW, Wang YC, et al. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012;11:1703\u201312.","journal-title":"Mol Cancer Ther"},{"key":"4197_CR44","doi-asserted-by":"publisher","first-page":"e29290","DOI":"10.1371\/journal.pone.0029290","volume":"6","author":"W Lu","year":"2011","unstructured":"Lu W, Lin C, Roberts MJ, et al. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt\/beta-catenin pathway. PLoS One. 2011;6:e29290.","journal-title":"PLoS One"},{"key":"4197_CR45","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-13-0095","volume":"12","author":"R Li","year":"2013","unstructured":"Li R, Hu Z, Sun SY, et al. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol Cancer Ther. 2013;12:2200\u201312.","journal-title":"Mol Cancer Ther"},{"key":"4197_CR46","doi-asserted-by":"crossref","first-page":"34630","DOI":"10.18632\/oncotarget.8969","volume":"7","author":"RL Stewart","year":"2016","unstructured":"Stewart RL, Carpenter BL, West DS, et al. S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide. Oncotarget. 2016;7:34630\u201342.","journal-title":"Oncotarget"},{"key":"4197_CR47","doi-asserted-by":"publisher","first-page":"e74670","DOI":"10.1371\/journal.pone.0074670","volume":"8","author":"R Li","year":"2013","unstructured":"Li R, You S, Hu Z, et al. Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. PLoS One. 2013;8:e74670.","journal-title":"PLoS One"},{"key":"4197_CR48","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1038\/bcj.2011.38","volume":"1","author":"FL Khanim","year":"2011","unstructured":"Khanim FL, Merrick BA, Giles HV, et al. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. Blood Cancer J. 2011;1:e39.","journal-title":"Blood Cancer J"},{"key":"4197_CR49","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0163-7258(82)90064-X","volume":"19","author":"P Andrews","year":"1982","unstructured":"Andrews P, Thyssen J, Lorke D. The biology and toxicology of molluscicides, bayluscide. Pharmacol Ther. 1982;19:245\u201395.","journal-title":"Pharmacol Ther"},{"key":"4197_CR50","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van CE, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303\u201312.","journal-title":"Lancet"},{"key":"4197_CR51","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"CE Van","year":"2012","unstructured":"Van CE, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30:3499\u2013506.","journal-title":"J Clin Oncol"},{"key":"4197_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1\u201310.","journal-title":"Control Clin Trials"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4197-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T09:51:58Z","timestamp":1603965118000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4197-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4197"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4197-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"28 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Susen Burock: Charit\u00e9 Comprehensive Cancer Center, Invalidenstra\u00dfe 80, 10117 Berlin, Germany.Severin Daum: Department of Medicine I, Gastroenterology, Rheumatology and Infectious Diseases, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Hindenburgdamm 30, 12200 Berlin, Germany.Ulrich Keilholz: Charit\u00e9 Comprehensive Cancer Center, Invalidenstra\u00dfe 80, 10117 Berlin, Germany and German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.Konrad Neumann: Charit\u00e9 Comprehensive Cancer Center, Invalidenstra\u00dfe 80, 10117 Berlin, Germany, Department for Biostatistics and Clinical Epidemiology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany.Wolfgang Walter: Experimental and Clinical Research Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin and Max-Delbr\u00fcck-Center for Molecular Medicine, Robert-R\u00f6ssle-Stra\u00dfe 10, 13125 Berlin, Germany.Ulrike Stein: Experimental and Clinical Research Center, Charit\u00e9 Universit\u00e4tsmedizin Berlin and Max-Delbr\u00fcck-Center for Molecular Medicine, Robert-R\u00f6ssle-Stra\u00dfe 10, 13125 Berlin, Germany and German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"The final protocol was approved by the ethics committee of the Landesamt f\u00fcr Gesundheit und Soziales (LAGeSo), Berlin, Germany and the Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) and is registered at EudraCT database (EudraCT 2014-005151-20) and at Clinicaltrials.gov (NCT02519582).This study complies with the Declaration of Helsinki in its recent version, the Medical Association\u2019s professional code of conduct, the principles of the International Conference on Harmonisation about Good Clinical Practice guidelines (ICH-GCP) and the Federal Data Protection Act. The trial will also be carried out in keeping with local legal and regulatory requirements. The medical secrecy and the Federal Data Protection Act will be followed.Written informed consent is obtained from each patient in oral and written form before inclusion in the trial and the nature, scope, and possible consequences of the trial have been explained by a physician. The investigator will not undertake any measures specifically required only for the clinical trial until valid consent has been obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests, besides the following patent applications:Stein U, Walther W, Sack U, Scudiero D, Schlag PM, Shoemaker RH. Niclosamide for treatment of cancer metastasis. US 14\/112,521(12.11.2013), EP2012\/057049 (18.4.2012).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"297"}}